By Bob Marshall, Chief Editor, Med Device Online
Who could have known a year ago that Becton Dickinson would purchase C. R. Bard for $24B or that Abbott would acquire St. Jude Medical for $25B? Who would have guessed the long-awaited new medical regulations would be enacted in Europe? Those positioned as leaders within the industry would be most likely to have seen those types of things coming, since they are heavily involved in what is going on and often connected to the ones making those decisions. I asked the following medtech leaders what changes they expect to see as we move forward into 2018.